Cns Pharmaceuticals Inc (CNSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,932 | -15,274 | -10,137 | -6,718 | -3,152 |
| Depreciation Amortization | 1 | 12 | 9 | 7 | 3 |
| Accounts payable and accrued liabilities | -877 | 2,304 | N/A | -665 | -666 |
| Other Working Capital | -184 | 3,164 | 960 | -354 | -266 |
| Other Operating Activity | 1,167 | -764 | 916 | 1,290 | 1,002 |
| Operating Cash Flow | $-4,825 | $-10,558 | $-8,253 | $-6,440 | $-3,077 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -4 | -4 | -3 | N/A |
| Investing Cash Flow | $N/A | $-4 | $-4 | $-3 | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 1 | 16,041 | 10,628 | 10,628 | 10,628 |
| Other Financing Activity | -121 | -428 | -349 | -231 | -115 |
| Financing Cash Flow | $-120 | $15,613 | $10,280 | $10,397 | $10,513 |
| Beginning Cash Position | 10,055 | 5,005 | 5,005 | 5,005 | 5,005 |
| End Cash Position | 5,111 | 10,055 | 7,028 | 8,959 | 12,441 |
| Net Cash Flow | $-4,945 | $5,051 | $2,023 | $3,954 | $7,436 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,825 | -10,558 | -8,253 | -6,440 | -3,077 |
| Capital Expenditure | N/A | -4 | -4 | -3 | N/A |
| Free Cash Flow | -4,825 | -10,562 | -8,257 | -6,443 | -3,077 |